Dr. Jitendra Singh Proposes India–Delaware Biomanufacturing Working Group

1. At a Glance

• Proposal by Union Minister of S&T Dr. Jitendra Singh for a structured India–Delaware (USA) Working Group on advanced biomanufacturing to translate dialogue into research, manufacturing and startup collaboration [S1].
• Announced during a meeting with US delegation led by Delaware Governor Matt Meyer at Seva Teerth, New Delhi on 02 March 2026 [S1].
• Locks into India's broader BioE3 Policy (2024) push to make India a top-5 global biomanufacturing hub; relevant for GS-II (IR) and GS-III (S&T, Economy).

2. Why in the News

• On 2 March 2026, Dr. Jitendra Singh proposed a small India–Delaware working group during a bilateral call by Delaware Governor Matt Meyer covering pharma, biotech, clean energy, and innovation-led industrial growth [S1].
• Comes amid broader India–US biotech engagement on supply-chain de-risking and regulatory cooperation [S1].

3. Background & Evolution

• Aug 2024: Union Cabinet approved the BioE3 (Biotechnology for Economy, Environment & Employment) Policy for high-performance biomanufacturing [S2].
• 2024: Minister sets target — India to be among top 5 global bio-manufacturing hubs [S1, S2].
• 2025–26: DBT–BIRAC joint calls launched Mulankur (मूलांकुर) Bio-AI hubs under BioE3 [S2].
• Mar 2026: India–Delaware Working Group proposal — first state-level US biomanufacturing track [S1].

4. Core Static Facts

• Ministry: Ministry of Science & Technology; nodal Dept — Department of Biotechnology (DBT) [S1, S2].
• Industry arm: BIRAC (Biotechnology Industry Research Assistance Council) [S2].
• Enabling policy: BioE3 Policy, 2024 — focus on bio-based chemicals/polymers/enzymes, smart proteins, precision biotherapeutics, climate-resilient agriculture, carbon capture, marine & space biotech [S2].
• US partner reference: NIIMBL — National Institute for Innovation in Manufacturing Biopharmaceuticals (Delaware) [S1].
• Incubators supported by MoST: ~150 across academic institutions [S1].
• R&D&I Fund: ₹1 lakh crore Research, Development & Innovation Fund to catalyse private/deep-tech investment [S1].
• Venue / interlocutors: Seva Teerth, New Delhi; Delaware Governor Matt Meyer [S1].

5. Multi-Dimensional Analysis

Economic - Pairs India's cost-efficient manufacturing with Delaware's proximity to major US pharma majors for co-development of affordable biologics [S1]. - Leverages ₹1 lakh crore RDI Fund to crowd in private capital for deep-tech biomanufacturing [S1].

Scientific / Technological - Cooperation areas: AI-enabled bio-processes, rapid scale-up, next-generation biologics & vaccines [S1]. - Workforce co-training proposed in GMP manufacturing, regulatory science, quality systems [S1].

Geopolitical / Strategic - A sub-national (state-level) diplomacy track — Delaware, home to NIIMBL and major pharma corporate HQs, complements G2G iCET-style engagement [S1]. - Addresses biotech supply-chain resilience and regulatory convergence, reducing dependence on adversarial geographies [S1].

Administrative / Governance - Mechanism: small bilateral working group to convert dialogue → MoUs in research, manufacturing, startup linkage, translational bridges [S1]. - Builds on DBT–BIRAC's Mulankur Bio-AI hubs and Centre–State BioE3 MoU framework (e.g., Assam MoU) [S2].

6. Recent Developments (last 12-18 months)

• 24 Aug 2024: Cabinet approves BioE3 Policy alongside Vigyan Dhara scheme [S2].
• 2025: DBT–BIRAC joint call for Bio-AI Mulankur hubs under BioE3 [S2].
• 2025: DBT–Govt. of Assam sign Centre-State MoU under BioE3 [S2].
• 02 Mar 2026: Dr. Jitendra Singh proposes India–Delaware Biomanufacturing Working Group [S1].

7. Prelims Hooks

• India–Delaware Biomanufacturing Working Group proposed on 2 March 2026 [S1].
• Proposed by Union Minister Dr. Jitendra Singh (Ministry of Science & Technology) [S1].
• US side led by Delaware Governor Matt Meyer [S1].
• Meeting venue: Seva Teerth, New Delhi [S1].
• US reference body cited: NIIMBL — National Institute for Innovation in Manufacturing Biopharmaceuticals, located in Delaware [S1].
• BioE3 Policy approved by Union Cabinet on 24 August 2024 [S2].
• BioE3 stands for Biotechnology for Economy, Environment and Employment [S2].
• Nodal department: Department of Biotechnology (DBT); industry arm: BIRAC [S2].
• BioE3 focus sectors include smart proteins, precision biotherapeutics, bio-based chemicals/polymers/enzymes, climate-resilient agriculture, carbon capture, marine & space biotech [S2].
• DBT–BIRAC's bio-AI hubs scheme is named मूलांकुर (Mulankur) [S2].
• India's Ministry of S&T supports approx. 150 incubators in academia [S1].
• Government RDI Fund corpus: ₹1 lakh crore [S1].
• India's stated ambition: Global top-5 biomanufacturing hub [S2].
• BioE3 was approved with Vigyan Dhara scheme in the same Cabinet meeting [S2].

8. Mains Relevance

• GS-II: India and developments in foreign relations affecting India's interests — bilateral / sub-national diplomacy with the US.
• GS-III: Science & Technology — indigenisation & developments; Indian economy — industrial growth, biomanufacturing.
• Possible question stems: 1. "Discuss how the BioE3 Policy 2024, combined with bilateral mechanisms like the proposed India–Delaware Working Group, can position India as a global biomanufacturing hub." (GS-III) 2. "Sub-national diplomacy is emerging as a complementary track in India–US relations. Examine in the context of the proposed India–Delaware biotech partnership." (GS-II) 3. "Evaluate the role of DBT, BIRAC and RDI Fund in catalysing India's deep-tech bioeconomy." (GS-III)

9. Related Topics to Study Next

• BioE3 Policy 2024 — parent policy for the working group's substance.
• iCET (India–US Initiative on Critical & Emerging Technologies) — overarching S&T cooperation umbrella.
• National Biopharma Mission & BIRAC — institutional plumbing.
• ₹1 lakh crore RDI Fund / Anusandhan NRF — financing rail for deep-tech.
• Vigyan Dhara scheme (2024) — companion S&T umbrella scheme.
• PLI Scheme for Pharma & Bulk Drugs — supply-chain de-risking complement.
• India's Bioeconomy ($300+ bn target) — macro target frame.
• Mulankur Bio-AI Hubs — operational layer under BioE3.

10. Common Errors / Trap Areas

• Delaware is a US state, not a federal agency — partnership is sub-national, not a G2G treaty.
• BioE3 was approved in Aug 2024, not 2023; do not confuse with the older National Biotechnology Development Strategy.
• Nodal ministry is Ministry of Science & Technology / DBT, not Ministry of Chemicals & Fertilizers (which handles pharma PLI).
• NIIMBL is a US (Delaware-based) institute; do not confuse with India's NIBMG or NII.
• BioE3's "E3" = Economy, Environment, Employment — not "Energy" or "Education".

11. Sources

• [S1] Dr. Jitendra Singh Proposes India–Delaware Biomanufacturing Working Group — https://www.pib.gov.in/PressReleasePage.aspx?PRID=2234522 — (tier 1)
• [S2] Cabinet approves BioE3 Policy for Fostering High Performance Biomanufacturing — https://www.pib.gov.in/PressReleaseIframePage.aspx?PRID=2048569 — (tier 1)